Johnson & Johnson (JNJ) Depreciation & Amortization (CF) (2009 - 2026)
Johnson & Johnson (JNJ) posted Depreciation & Amortization (CF) of $2.0 billion for Q2 2026, down 2.25% sequentially from $2.0 billion in Q1 2026, and up 0.82% YoY from $1.9 billion in Q2 2025.
Johnson & Johnson (JNJ) Depreciation & Amortization (CF) (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Depreciation & Amortization (CF) for 18 years, with the latest figure at $2.0 billion in Q2 2026.
- Quarterly Depreciation & Amortization (CF) rose 0.82% year-over-year to $2.0 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $7.8 billion (up 3.94% YoY) and the FY2025 annual result came in at $7.5 billion, up 2.23% from the prior year.
- Depreciation & Amortization (CF) fell to $2.0 billion in Q2 2026 per JNJ's latest filing, from $2.0 billion in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $2.0 billion in Q4 2025 and troughed at $1.4 billion in Q1 2023.
- A 5-year average of $1.8 billion and a median of $1.8 billion in 2023 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2023 and 2024: Depreciation & Amortization (CF) climbed 29.52% in 2023, then decreased 7.86% in 2024.
- Over 5 years, Depreciation & Amortization (CF) stood at $1.8 billion in 2022, then advanced by 4.18% to $1.8 billion in 2023, then rose by 2.88% to $1.9 billion in 2024, then gained by 6.07% to $2.0 billion in 2025, then declined by 2.59% to $2.0 billion in 2026.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $2.0 billion, $2.0 billion, and $2.0 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 1.96 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 1.11 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 1.62 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 1.96 Bn |
| Jun 28, 2026 | 1.96 Bn |
| Mar 29, 2026 | 2.00 Bn |
| Mar 29, 2026 | 2.00 Bn |
| Dec 28, 2025 | 2.01 Bn |
| Dec 28, 2025 | 2.01 Bn |
| Sep 28, 2025 | 1.78 Bn |
| Sep 28, 2025 | 1.78 Bn |
| Jun 29, 2025 | 1.94 Bn |
| Jun 29, 2025 | 1.94 Bn |
| Mar 30, 2025 | 1.77 Bn |
| Mar 30, 2025 | 1.77 Bn |
| Dec 29, 2024 | 1.90 Bn |
| Dec 29, 2024 | 1.90 Bn |
| Sep 29, 2024 | 1.85 Bn |
| Sep 29, 2024 | 1.85 Bn |
| Jun 30, 2024 | 1.78 Bn |
| Jun 30, 2024 | 1.78 Bn |
| Mar 31, 2024 | 1.82 Bn |
| Mar 31, 2024 | 1.82 Bn |